Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.45 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CTSV | O60911 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29805068 | 0.90 | ALDH1A1 (0.52) | ALDH1A1HPGDSGMS2PIN1POLB | |
| SCHEMBL8967901 | 0.90 | ALDH1A1 (0.52) | ALDH1A1HPGDSGMS2PIN1POLB | |
| SCHEMBL1401807 | 0.86 | ALDH1A1 (0.48) | ALDH1A1HPGDSGMS2PIN1POLB | |
| SCHEMBL4373962 | 0.84 | ALDH1A1 (0.46) | ALDH1A1HPGDSGMS2POLBMEN1 | |
| SCHEMBL18863826 | 0.82 | POLB (0.54) | HPGDSGMS2PIN1POLBMEN1 | |
| SCHEMBL29894219 | 0.82 | POLB (0.54) | HPGDSGMS2PIN1POLBMEN1 | |
| SCHEMBL2568216 | 0.79 | PIN1 (0.52) | SGMS2PIN1POLBMEN1KMT2A | |
| SCHEMBL8388636 | 0.79 | ALDH1A1 (0.55) | ALDH1A1HPGDSGMS2MEN1KMT2A | |
| SCHEMBL1193049 | 0.79 | PIN1 (0.49) | ALDH1A1PIN1POLBMEN1KMT2A | |
| SCHEMBL3351038 | 0.79 | PIN1 (0.49) | PIN1POLBMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024220852-A2 | TEAD CORE INHIBITORS FOR CANCER THERAPEUTICS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-10-24 | — | — | WO | disclosed |
| US-9828378-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828378-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-11-28 | — | — | US | disclosed |
| EP-2960238-B1 | MONOCYCLIC PYRIDINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2017-04-05 | — | — | EP | disclosed |
| EP-2960238-B1 | MONOCYCLIC PYRIDINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2017-04-05 | — | — | EP | disclosed |
| EP-3009436-A1 | KINASE INHIBITORS AND METHODS OF USE | Intellikine, LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20160024099-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2016-01-28 | — | — | US | disclosed |
| US-20160024099-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2016-01-28 | — | — | US | disclosed |
| EP-2960238-A1 | MONOCYCLIC PYRIDINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2015-12-30 | — | — | EP | disclosed |
| EP-2960238-A1 | MONOCYCLIC PYRIDINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2015-12-30 | — | — | EP | disclosed |
| EP-2402314-B1 | (Aza)indole derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL (JP) | 2013-07-31 | — | — | EP | disclosed |
| US-8466152-B2 | (aza)indole derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2013-06-18 | — | — | US | disclosed |
| EP-2402314-A1 | (Aza)indole derivative and use thereof for medical purposes | Kissei Pharmaceutical Co., Ltd. (JP) | 2012-01-04 | — | — | EP | disclosed |
| US-20110230454-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-09-22 | — | — | US | disclosed |
| US-8003647-B2 | (Aza)indole derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-23 | — | — | US | disclosed |
| US-20110172228-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-07-14 | — | — | US | disclosed |
| US-20110172228-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-07-14 | — | — | US | disclosed |
| US-20100056521-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| WO-2010006086-A2 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| EP-2133332-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | Kissei Pharmaceutical Co., Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172228-A1 | KINASE INHIBITORS AND METHODS OF USE | PIK3CA, MTOR, PDPK1 | ALDH1A1 4685/4885HPGD 3341/4885SGMS2 974/4885 |
| US-20100056521-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, DAO, TDO2 | ALDH1A1 424/4885HPGD 178/4885SGMS2 2228/4885 |
| US-20160024099-A1 | KINASE INHIBITORS AND METHODS OF USE | PIK3CA, MTOR, PDPK1 | ALDH1A1 4685/4885HPGD 3341/4885SGMS2 974/4885 |
| US-20110230454-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, DAO, TDO2 | ALDH1A1 424/4885HPGD 178/4885SGMS2 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.